ImmuneOnco Biopharmaceuticals (Shanghai) Future Growth
Future criteria checks 0/6
ImmuneOnco Biopharmaceuticals (Shanghai)'s revenue is forecast to decline at 81.8% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 43.0% |
| Revenue growth rate | -81.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Aug 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 1 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 1 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 7 | -374 | -366 | -358 | N/A |
| 3/31/2024 | 7 | -377 | -368 | -363 | N/A |
| 12/31/2023 | 8 | -379 | -370 | -368 | N/A |
| 9/30/2023 | 8 | -371 | -328 | -324 | N/A |
| 6/30/2023 | 6 | -362 | -286 | -280 | N/A |
| 3/31/2023 | 6 | -382 | -274 | -259 | N/A |
| 12/31/2022 | 6 | -403 | -262 | -239 | N/A |
| 12/31/2021 | 14 | -733 | -231 | -191 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1541's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1541's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1541's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1541's revenue is expected to decline over the next 3 years (-81.8% per year).
High Growth Revenue: 1541's revenue is forecast to decline over the next 3 years (-81.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1541's Return on Equity is forecast to be high in 3 years time